AR019505A1 - Composicion farmaceutica y usos de la misma para tratar infecciones virales - Google Patents

Composicion farmaceutica y usos de la misma para tratar infecciones virales

Info

Publication number
AR019505A1
AR019505A1 ARP000101499A ARP000101499A AR019505A1 AR 019505 A1 AR019505 A1 AR 019505A1 AR P000101499 A ARP000101499 A AR P000101499A AR P000101499 A ARP000101499 A AR P000101499A AR 019505 A1 AR019505 A1 AR 019505A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
viral infections
same
treat viral
thiourea
Prior art date
Application number
ARP000101499A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR019505A1 publication Critical patent/AR019505A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica que inhibe o detiene el crecimiento de virus en animales, particularmente en mamíferos. La composicion comprende de 10mg a 6000 mg, aproximadamente, de un derivado de (5-aril-1,2,4-tiadiazol)-3-il tiourea o derivado de (5-aril-1,2,4-tia-diazol)-3-il urea de laformula (1). Tratamiento de infecciones virales, particularmente hepatitis C, herpes simplex y VIH, en animales, particularmente en mamíferos.Formula (I), en donde X es oxígeno o azufre, R es hidrogeno o alquiloque tiene C1-3, n es 0-4; R1 independientemente se selecciona delgrupo que consiste de hidrogeno, alquilo que tiene C1-7, cloro, bromo o fluor, oxicloro, alcoxi que tiene la formula O(CH2)yCH3 en donde y es de 1a 6 o una sal de adicion farmacéuticaso prodrogas de ésta. El compuesto preferido es (5-fenil-1,2,4-tiadiazol)-3-il-tiourea.
ARP000101499A 1999-03-31 2000-03-31 Composicion farmaceutica y usos de la misma para tratar infecciones virales AR019505A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189699A 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
AR019505A1 true AR019505A1 (es) 2002-02-20

Family

ID=23079226

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101499A AR019505A1 (es) 1999-03-31 2000-03-31 Composicion farmaceutica y usos de la misma para tratar infecciones virales

Country Status (11)

Country Link
US (2) US6258831B1 (es)
EP (1) EP1165070B1 (es)
JP (1) JP2002540156A (es)
AR (1) AR019505A1 (es)
AT (1) ATE297729T1 (es)
AU (1) AU763573B2 (es)
CA (1) CA2368615C (es)
CO (1) CO5160294A1 (es)
DE (1) DE60020820T2 (es)
PE (1) PE20001644A1 (es)
WO (1) WO2000057878A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423695B1 (en) * 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
US6245788B1 (en) * 1999-03-31 2001-06-12 The Procter & Gamble Company Viral treatment
DE10120627A1 (de) * 2001-04-26 2002-10-31 Cmi Ag Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
AU2003231766A1 (en) 2002-04-26 2003-11-10 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US20040010036A1 (en) * 2002-05-07 2004-01-15 Boris Rogovoy N,N, -Substituted s-Aryl-Isothioureas, N,N,N, -Substituted s-Aryl-Isothioureas and combinatorial libraries thereof
EP1599217B1 (en) * 2002-11-18 2014-04-16 Polaris Group Methods for inhibiting viral replication in vivo
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
CA2522845A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004096287A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
EP1628685B1 (en) * 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
AU2004290298A1 (en) 2003-10-24 2005-05-26 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
US7253175B2 (en) * 2003-11-13 2007-08-07 Barnet Liberman Method for treating athlete's foot
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
ME03423B (me) 2004-07-27 2020-01-20 Gilead Sciences Inc Fosfonatni analozi jedinjenja hiv inhibitora
US20060264422A1 (en) * 2005-05-09 2006-11-23 Johannes Reinmueller Use of taurolidine as enhancer of the complement system
JP2009510122A (ja) * 2005-09-29 2009-03-12 ザ スクリプス リサーチ インスティテュート ウイルスペプチドおよびフラビウイルス科のウイルスに対してウイルス感染を阻害するためのその使用
US7480400B2 (en) * 2006-03-16 2009-01-20 Siemens Medical Solutions Usa, Inc. Detection of fiber pathways
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
EP3661937B1 (en) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) for treating viral infections
CN112752761B (zh) * 2018-08-21 2024-03-29 杏林制药株式会社 双环杂芳族环衍生物
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353920A (en) * 1980-08-25 1982-10-12 Olin Corporation Use of selected 3-trihalomethyl-5-ureido-1,2,4-oxadiazoles and -1,2,4-thiadiazoles as agricultural viricides
JPS57136579A (en) * 1981-01-21 1982-08-23 Mitsui Toatsu Chem Inc Thiazolylurea derivative, its preparation, and pharmaceutical composition containing the same
US4835168A (en) * 1985-12-16 1989-05-30 Eli Lilly And Company Thiadiazole antiviral agents
US5256680A (en) * 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
US5593993A (en) 1991-08-02 1997-01-14 Medivir Ab Method for inhibition of HIV related viruses
IL102548A (en) 1991-08-02 1998-08-16 Medivir Ab Use of painting derivatives in the preparation of drugs for VIH inhibition and treatment of SDIA and new compounds
JPH07149748A (ja) * 1993-09-30 1995-06-13 Souyaku Gijutsu Kenkyusho:Kk チアジアゾール誘導体及びその製造法
JPH08169881A (ja) * 1994-09-22 1996-07-02 Soyaku Gijutsu Kenkyusho:Kk アリールチアジアゾール誘導体及びそれを含有する抗ウイルス剤
JPH08245384A (ja) * 1995-03-13 1996-09-24 Soyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
US6162791A (en) 1998-03-02 2000-12-19 Apotex Inc. Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes

Also Published As

Publication number Publication date
US6258831B1 (en) 2001-07-10
DE60020820T2 (de) 2006-05-04
US6410575B2 (en) 2002-06-25
CA2368615A1 (en) 2000-10-05
EP1165070A1 (en) 2002-01-02
EP1165070B1 (en) 2005-06-15
WO2000057878A1 (en) 2000-10-05
JP2002540156A (ja) 2002-11-26
ATE297729T1 (de) 2005-07-15
AU4182200A (en) 2000-10-16
US20010031773A1 (en) 2001-10-18
CO5160294A1 (es) 2002-05-30
CA2368615C (en) 2007-01-02
DE60020820D1 (de) 2005-07-21
AU763573B2 (en) 2003-07-24
PE20001644A1 (es) 2001-02-06

Similar Documents

Publication Publication Date Title
AR019505A1 (es) Composicion farmaceutica y usos de la misma para tratar infecciones virales
AR019305A1 (es) Hiv y tratamiento viral.
BR9916772A (pt) Quinolinacarboxamidas como agentes antivirais
NZ507032A (en) 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections
TW427887B (en) Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections
AR018706A1 (es) Uso de una composicion farmaceutica para tratamiento de infecciones virales
HUP9900901A2 (hu) N-(Klór-fenil)-karbamátokat és N-(klór-fenil)-tiokarbamátokat tartalmazó, rákellenes és vírusok szaporodását gátló gyógyszerkészítmény
AU590824B2 (en) Synergistic composition and method of selectively controlling weeds in cereals
AR037940A1 (es) Compuestos antivirales de piridoquinoxalina
PE61699A1 (es) Composicion farmaceutica de lamivudina
CO5160293A1 (es) Composicion farmaceutica que inhibe o detiene la infeccion o reinfeccion de animales, particularmente mamiferos, por vih u otros retroviruses
NZ241530A (en) Hydroxamic acid and n-hydroxy urea derivatives and pharmaceutical compositions
KR900014343A (ko) N-(시아노메틸)-벤조-1,2,3-티아디아졸-7-카르복시아미드 및 그의 제조방법
FI822282A0 (fi) Foerfarande foer framstaellning av , -dialkyladamantyletylaminer med antivirus verkan
KR940005612A (ko) 벤조디아제핀
KR890002134A (ko) 1,2-벤즈 이속 사졸 및 1,2-벤즈 이소 티아졸 유도체
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
AU2689192A (en) Benzoxazole, benzothiazole and benzimidazole derivatives as fungicides
KR950701627A (ko) 벤조티아졸 화합물, 그의 제조방법 및 용도(benzothiazole compound, process for producing the same, and use thereof)
KR910700054A (ko) B형 간염 비루스 감염의 예방 및 치료를 위한 방법 및 조성물
KR910021407A (ko) 바이러스에 의해 유발된 질환을 치료하기 위한 벤질포스폰산 유도체의 용도
NZ514560A (en) Viral treatment
KR900017587A (ko) 바이러스 감염증 치료제의 제조를 위한 티아졸 유도체 티프로티모드의 용도
EP0355279A3 (en) Use of nitrogen-containing compounds as antiparasitics, and compositions containing them
ATE158503T1 (de) Aids-virus-infektion hemmende zusammensetzung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal